Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022, with a specific transaction date of March 23, 2022. The document serves as a transaction notification regarding share allocations for Non-Executive Directors under the company's share allocation arrangements for the service period of January 1, 2022, to March 31, 2022.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific equity transactions involving the following instruments and prices:
- Ordinary Shares (GBP): Priced at £15.90 per share.
- American Depositary Shares (ADSs) (USD): Priced at $42.28 per ADS.
Material Changes
The filing reports no material changes to the company's financial position or operations. It documents routine acquisitions of notional shares by Persons Discharging Managerial Responsibilities (PDMRs) as part of their compensation structure. No comparative data against prior periods is provided within this specific transaction notification.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of Ordinary Shares and ADSs allocated to Non-Executive Directors for the Q1 2022 period.
- Confirm the transaction price of £15.90 for Ordinary Shares and $42.28 for ADSs against market prices on March 23, 2022.
- Review the full list of Non-Executive Directors involved: Sir Jonathan Symonds, Mr Charles Bancroft, Mr Vindi Banga, Dr Anne Beal, Dame Vivienne Cox, Dr Hal Dietz, Ms Lynn Elsenhans, Dr Laurie Glimcher, Dr Jesse Goodman, and Mr Urs Rohner.
- Note that this filing does not contain financial performance data; refer to the company's Form 20-F or quarterly earnings releases for revenue and profit metrics.